Clinical Review
Use of antibiotics in the treatment of inflammatory bowel disease
Molly Perencevich MD,
Robert Burakoff MD, MPH,
Molly Perencevich MD
Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorCorresponding Author
Robert Burakoff MD, MPH
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts
Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115Search for more papers by this authorMolly Perencevich MD,
Robert Burakoff MD, MPH,
Molly Perencevich MD
Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorCorresponding Author
Robert Burakoff MD, MPH
Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts
Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA 02115Search for more papers by this authorAbstract
An increasing amount of evidence suggests that enteric flora may have a role in the pathogenesis of inflammatory bowel disease (IBD). Patients with IBD appear to have an altered composition of luminal bacteria that may providethe stimulus for the chronic inflammation characterizing IBD. The suspected role of bacteria in the pathogenesis of IBD provides the rationale for using agents, such as antibiotics, that alter the intestinal flora. However, there remains much uncertainty about the optimal use of antibiotics in the treatment of Crohn's disease, ulcerative colitis, and pouchitis. This article reviews the literature and presents a clinical model for the use of antibiotics in IBD.
References
- 1 Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 1997; 92 (Suppl 12): 5S–11S.
- 2 Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol. 2001; 17: 324–330.
- 3 Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417–429.
- 4 Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31: 41–62.
- 5 Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: S16–S24.
- 6 Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2-microglobulin transgenic rats. J Clin Invest. 1996; 98: 945–953.
- 7 Dianda L, Hanby AM, Wright NA, et al. T cell receptor-αβ-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol. 1997; 150: 91–97.
- 8 Sellon RK, Tonkonogy S, Shultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66: 5224–5231.
- 9 Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991; 337: 771–774.
- 10 D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114: 262–267.
- 11 Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122: 44–54.
- 12 Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. Gut. 2004; 53: 1–4.
- 13 Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002; 97: 939–946.
- 14Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127: 412–421.
- 15 Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005; 43: 3380–3389.
- 16 Shanahan F, O'Mahony J. The mycobacteria story in Crohn's disease. Am J Gastroenterol. 2005; 100: 1537–1538.
- 17 Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995; 102: 448–455.
- 18 Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996; 38: 365–375.
- 19 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599–603.
- 20 Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603–606.
- 21 Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003; 124: 993–1000.
- 22 Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003; 278: 8869–8872.
- 23 Barnich N, Aguirre JE, Reinecker HC, et al. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-κB activation in muramyl dipeptide recognition. J Cell Biol. 2005; 170: 21–26.
- 24 Wekhamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut. 2004; 53: 1658–1664.
- 25 Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731–734.
- 26 Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002; 122: 867–874.
- 27 Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis. 2005; 11(Suppl 1): S3–S12.
- 28 Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004; 126: 1620–1633.
- 29 Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am. 2004; 33: 335–345.
- 30 Thukral C, Travassos WJ, Peppercorn MA. The role of antibiotics in inflammatory bowel disease. Curr Treat Options Gastroenterol. 2005; 8: 223–228.
- 31 Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol. 2005; 17: 145–147.
- 32 Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20: 75–78.
- 33 Ohkusa T, Sato N. Antibacterial and antimycobacterial treatment for inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 340–351.
- 34 Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003; 98: S18–S23.
- 35 Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982; 83: 383–387.
- 36 Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology. 1985; 88: 681–684.
- 37 Stahlberg D, Barany F, Einarsson K, et al. Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole. Scand J Gastroenterol. 1991; 26: 219–224.
- 38 Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003; 36: 1404–1410.
- 39 Williams RJ III, Attia E, Wickiewicz TL, et al. The effect of ciprofloxacin on tendon, paratendon, and capsular fibroblast metabolism. Am J Sports Med. 2000; 28: 364–369.
- 40 Sendzik J, Shakibaei M, Schafer-Korting M, et al. Fluoroquinolones cause changes in extracellular matrix, signaling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology. 2005; 212: 24–36.
- 41 Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004; 99: 656–661.
- 42 Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001; 30: 753–777.
- 43 Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983; 18: 61–64.
- 44 LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980; 1: 381–383.
- 45 Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980; 1: 383–384.
- 46 Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981; 80: 693–696.
- 47 Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983; 24: 713–717.
- 48 Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981; 80: 697–700.
- 49 Burke DA, Axon AT. Clostridium difficile, sulphasalazine, and ulcerative colitis. Postgrad Med J. 1987; 63: 955–957.
- 50 Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut. 2004; 53: 246–250.
- 51 Aberra FN, Brensinger CM, Bilker WB, et al. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005; 3: 459–465.
- 52 Logan RF. Antibiotics and flare of inflammatory bowel disease: threat or therapy? Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 446–447.
- 53 Ursing B, Kamme C. Metronidazole in Crohn's disease. Lancet. 1975; 1: 775–777.
- 54 Allan R, Cooke WT. Evaluation of metronidazole in the management of Crohn's disease. Gut. 1977; 18: A422.
- 55 Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn's disease: a double blind cross-over clinical trial. Scand J Gastroenterol. 1978; 13: 123–127.
- 56 Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991; 32: 1071–1075.
- 57 Rosen A, Ursing B, Alm T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology. 1982; 83: 541–549.
- 58 Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology. 1982; 83: 550–562.
- 59 Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol. 1993; 17: 235–237.
- 60 Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol. 1999; 94: 674–678.
- 61 Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002; 8: 10–15.
- 62 Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996; 91: 328–332.
- 63 Prantera C, Berto E, Scribano ML, et al. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol. 1998; 30: 602–606.
- 64 Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol. 1998; 12: 53–56.
- 65 Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002; 123: 33–40.
- 66 Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis. 2004; 10: 318–320.
- 67 Wild GE. The role of antibiotics in the management of Crohn's disease. Inflamm Bowel Dis. 2004; 10: 321–323.
- 68 Shanahan F, Bernstein CN. Antibiotics as a first-line therapy for Crohn's disease: is there any consensus? Inflamm Bowel Dis. 2004; 10: 324–326.
- 69 Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med. 2001; 135: 906–918.
- 70 Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980; 79: 357–365.
- 71 Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984; 79: 533–540.
- 72 Turunen U, Farkkila M, Seppala K. Long-term treatment of perianal or fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol. 1989; 24(Suppl 158): 144.
- 73 Wolf JL. Ciprofloxacin may be useful in Crohn's disease. Gastroenterology. 1990; 98: A212.
- 74 Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003; 18: 1113–1120.
- 75 Theal J, Haider MA, Greenberg GR. Meropenem improves complex perianal Crohn's disease refractory to infliximab. Gastroenterology. 2004; 126: A627.
- 76 West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004; 20: 1329–1336.
- 77 Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn's disease. Inflamm Bowel Dis. 2005; 11: 765–777.
- 78 Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956–963.
- 79 Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995; 108: 1617–1621.
- 80 Rutgeerts P, van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005; 128: 856–861.
- 81 Dalziel TK. Chronic interstitial enteritis. BMJ. 1913; 2: 1068–1070.
- 82 Morgan KL. Johne's and Crohn's: chronic inflammatory bowel diseases of infectious aetiology? Lancet. 1987; 1: 1017–1019.
- 83 Ryan P, Bennett MW, Aarons S, et al. PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut. 2002; 51: 665–670.
- 84 Bull TJ, McMinn EJ, Sidi-Boumedine K, et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol. 2003; 41: 2915–2923.
- 85 Naser SA, Ghobrial G, Romero C, et al. Culture of mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet. 2004; 364: 1039–1044.
- 86 Sechi LA, Scanu AM, Molicotti P, et al. Detection and isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol. 2005; 100: 1529–1536.
- 87 Hulten K, Almashhrawi A, El-Zaatari FA, et al. Antibacterial therapy for Crohn's disease: a review emphasizing therapy against mycobacteria. Dig Dis Sci. 2000; 45: 445–456.
- 88 Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504–1517.
- 89 Elliott PR, Burnham WR, Berghouse LM, et al. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion. 1982; 23: 132–134.
- 90 Kelleher D, O'Brien S, Weir DG. Preliminary trial of clofazimine in chronic inflammatory bowel disease. Gut. 1982; 23: A449.
- 91 Shaffer JL, Hughes S, Linaker BD, et al. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut. 1984; 25: 203–205.
- 92 Warren JB, Rees HC, Cox TM. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med. 1986; 314: 182.
- 93 Schultz MG, Rieder HL, Hersh T, et al. Remission of Crohn's disease with antimycobacterial chemotherapy. Lancet. 1987; 2: 1391–1392.
- 94 Jarnerot G, Rolny P, Wickbom G, et al. Antimycobacterial therapy ineffective in Crohn's disease after a year. Lancet. 1989; 1: 164–165.
- 95 Hampson SJ, Parker MC, Saverymuttu SH, et al. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther. 1989; 3: 343–352.
- 96 Basilisco G, Ranzi T, Campanini MC, et al. Controlled trial of rifabutin in Crohn's disease. Curr Ther Res. 1989; 46: 245–250.
- 97 Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease: clofazimine versus placebo. Dig Dis Sci. 1991; 36: 449–453.
- 98 Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol. 1992; 15: 24–28.
- 99 Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994; 89: 513–518.
- 100 Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut. 1994; 35: 363–368.
- 101 Thomas GAO, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut. 1998; 42: 497–500.
- 102 Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology. 1995; 108: A826.
- 103 Douglass A, Cann PA, Bramble MG. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn's disease. Gut. 2000; 46: A11.
- 104 Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther. 2000; 14: 801–806.
- 105 Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 1999: CD000299.
- 106 Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol. 2000; 95: 725–729.
- 107 Goodgame RW, Kimball K, Akram S, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther. 2001; 15: 1861–1866.
- 108 Gui GP, Thomas PR, Tizard ML, et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother. 1997; 39: 393–400.
- 109 Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis. 2002; 34: 22–28.
- 110 Borody TJ, Leis S, Warren EF, et al. Treatment of severe Crohn's disease using antimycobacterial triple therapy: approaching a cure? Dig Liver Dis. 2002; 34: 29–38.
- 111 Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004; 33: 235–250.
- 112 Gilat T, Suissa A, Leichtman G, et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. J Clin Gastroenterol. 1987; 9: 415–417.
- 113 Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986; 27: 1210–1212.
- 114 Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997; 92: 454–456.
- 115 Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001; 36: 971–974.
- 116 Turunen U, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998; 115: 1072–1078.
- 117 Peppercorn MA. Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol. 1993; 17: 14–17.
- 118 Burke DA, Axon AT, Clayden SA, et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990; 4: 123–129.
- 119 Lobo AJ, Burke DA, Sobala GM, et al. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 1993; 7: 155–158.
- 120 Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994; 89: 43–46.
- 121 Casellas F, Borruel N, Papo M, et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis. 1998; 4: 1–5.
- 122 Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol. 2005; 40: 1334–1342.
- 123 Shen B, Fazio VW, Remzi FH, et al. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005; 100: 2796–2807.
- 124 Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994; 107: 1856–1860.
- 125 Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology. 2004; 127: 1809–1814.
- 126 Gionchetti P, Amadini C, Rizzello F, et al. Diagnosis and treatment of pouchitis. Best Pract Res Clin Gastroenterol. 2003; 17: 75–87.
- 127 Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994; 39: 1193–1196.
- 128 Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis: a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther. 2002; 16: 27–34.
- 129 Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001; 7: 301–305.
- 130 Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002; 16: 909–917.
- 131 Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999; 13: 713–718.
- 132 Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005; 51(Suppl 1): 36–66.
- 133 Gionchetti P, Rizzello F, Morselli C, et al. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy. 2005; 51(Suppl 1): 96–102.
- 134 Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin. 2005; 21: 1165–1169.
- 135 Kornbluth A, Hunt M, George J, et al. Efficacy and safety of rifaximin in the treatment of mild-moderate Crohn's disease: results of an open-label pilot study. Gastroenterology. 2005; 128: A579.
- 136 Bosworth BP, Scherl EJ. A novel nonabsorbable antibiotic (rifaximin) in the treatment of moderate to severe Crohn's disease. Gastroenterology. 2005; 128: A576.
- 137
Baidoo L, et al.
Gastroenterology.
2005;
128:
A238.
10.1053/j.gastro.2004.11.026 Google Scholar
- 138 Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999; 44: 1220–1221.
- 139 Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: an open label study. Gastroenterology. 2002; 122: A434.
- 140 Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res. 2004; 65: 292–296.
- 141 Baidoo L, Kundu R, Su C, et al. Rifaximin is an effective antibiotic for the treatment of pouchitis. Gastroenterology. 2005; 128: A797.
- 142 Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 286–299.
- 143 Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol Clin North Am. 2005; 34: 465–482.
- 144 Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003; 124: 1202–1209.
- 145 Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119: 305–309.
- 146 Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004; 53: 108–114.
- 147 Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study versus mesalamine. Gastroenterology. 2000; 118: A781.
- 148 Lichtenstein GR, Hanauer SB, Kane SV, et al. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004; 10(Suppl 2): S2–S10.
